Int. J. Mol. Sci. 2012, 13(12), 16624-16635; doi:10.3390/ijms131216624
Article

Modulation of MDR1 and MRP3 Gene Expression in Lung Cancer Cells after Paclitaxel and Carboplatin Exposure

1 Institute of Biopathology and Regenerative Medicine (IBIMER), Department of Anatomy and Human Embryology, School of Medicine, University of Granada, Granada E-18071, Spain 2 Service of Medical Oncology, Virgen de las Nieves Hospital, Granada E-18012, Spain 3 Department of Health Science, University of Jaén, Jaén E-23071, Spain These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 28 September 2012; in revised form: 20 November 2012 / Accepted: 26 November 2012 / Published: 5 December 2012
(This article belongs to the Special Issue Advances in Molecular Oncology)
PDF Full-text Download PDF Full-Text [458 KB, uploaded 5 December 2012 10:34 CET]
Abstract: Carboplatin-paclitaxel is a reference regimen in the treatment of locally advanced or disseminated non-small cell lung cancer (NSCLC). This paper discusses the multidrug resistance developed with this drug combination, which is one of the major obstacles to successful treatment. In order to understand and overcome the drug resistance pattern of NSCLC after carboplatin plus paclitaxel exposure, levels of mRNA expression of multidrug resistance 1 (MDR1) and multidrug resistance-associated protein 3 (MRP3) were investigated in primary NSCLC cell lines (A-549 and A-427) and a metastasis-derived NSCLC cell line (NODO). Our results showed that exposure of the three NSCLC lines to plasma concentrations of paclitaxel (5 μM) produced an increase in MDR1 expression, while MRP3 showed no alteration in expression. By contrast, the same cells exposed to carboplatin plasma concentrations (30 μM) showed overexpression of MRP3. In these cells, MDR1 showed no expression changes. Interestingly, the combination of both paclitaxel and carboplatin caused increased expression of the MDR1 drug resistance gene rather than the individual treatments. These results suggest that carboplatin and paclitaxel may induce drug resistance mediated by MDR1 and MRP3, which may be enhanced by the simultaneous use of both drugs.
Keywords: lung cancer; resistance; MDR; MRP; paclitaxel; carboplatin

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Melguizo, C.; Prados, J.; Luque, R.; Ortiz, R.; Caba, O.; Álvarez, P.J.; Gonzalez, B.; Aranega, A. Modulation of MDR1 and MRP3 Gene Expression in Lung Cancer Cells after Paclitaxel and Carboplatin Exposure. Int. J. Mol. Sci. 2012, 13, 16624-16635.

AMA Style

Melguizo C, Prados J, Luque R, Ortiz R, Caba O, Álvarez PJ, Gonzalez B, Aranega A. Modulation of MDR1 and MRP3 Gene Expression in Lung Cancer Cells after Paclitaxel and Carboplatin Exposure. International Journal of Molecular Sciences. 2012; 13(12):16624-16635.

Chicago/Turabian Style

Melguizo, Consolación; Prados, Jose; Luque, Raquel; Ortiz, Raúl; Caba, Octavio; Álvarez, Pablo J.; Gonzalez, Beatriz; Aranega, Antonia. 2012. "Modulation of MDR1 and MRP3 Gene Expression in Lung Cancer Cells after Paclitaxel and Carboplatin Exposure." Int. J. Mol. Sci. 13, no. 12: 16624-16635.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert